Not independent
Tenure on this board
0.8 yrs
Meeting calendar
SRTA · Annual meeting · Thursday, May 28, 2026
Strata Critical Medical Inc
2 nominees · 3 ballot items.
Elect two Class II directors; ratify appointment of Deloitte & Touche LLP as independent auditors for 2026; advisory (non-binding) vote to approve named executive officers’ 2025 compensation (Say-on-Pay).
Market cap
$457M
1Y TSR
+28.2%
Board grade
C+
Record date
Mar 31, 2026
Filing
DEF 14A
Meeting concluded · May 28, 2026
Follow how the vote landed and what changed on Strata Critical Medical Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Elect Class II Directors
ManagementBoard: FORElection of two Class II director nominees (William A. Heyburn and Andrew C. Lauck) to serve three-year terms expiring at the 2029 Annual Meeting.
- 2
Ratify Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 3
Advisory Vote on the Compensation of Our Named Executive Officers (Say-on-Pay
ManagementBoard: FORNon-binding advisory vote to approve the compensation of the Company's named executive officers as disclosed in the proxy statement for 2025.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
3.3 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 8.6% | 7,455,284 | $31M |
| 2 | Third Point LLCActivist | 5.8% | 5,000,000 | $21M |
| 3 | Northern Right Capital Management, L.P.Activist | 4.7% | 4,090,169 | $17M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 2,872,446 | $12M |
| 5 | AWM Investment Company, Inc.Activist | 3.3% | 2,821,468 | $12M |
| 6 | ROYCE ASSOCIATES LP | 3.3% | 2,816,372 | $12M |
| 7 | Pillsbury Lake Capital LLC | 3.0% | 2,603,796 | $11M |
| 8 | BlackRock, Inc. | 2.9% | 2,486,839 | $10M |
| 9 | First Eagle Investment Management, LLC | 2.6% | 2,265,107 | $9M |
| 10 | Sumitomo Mitsui Trust Group, Inc. | 1.9% | 1,654,361 | $7M |
Peers
Nearest market capOther Industrials sector meetings6
Upcoming shareholder meetings at Strata Critical Medical Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
D Boral Arc Acquisition I CorpBCAR
Special meeting·Jul 29, 2026·$422M
M3-brigade Acquisition V CorpMBAV
Special meeting·Jul 17, 2026·$391M
Ennis IncEBF
Annual meeting·Jul 16, 2026·$532M
Capstone Energy Plus IncCEPL
Annual meeting·Aug 20, 2026·$381M
Columbus Mckinnon CorpCMCO
Annual meeting·Aug 14, 2026·$380M
Inflection Point Acquisition Corp IIIIPCX
Special meeting·Jul 29, 2026·$359M
Reference
Frequently asked questions
- When is the Strata Critical Medical Inc 2026 annual meeting?
- Strata Critical Medical Inc (SRTA) holds its 2026 annual shareholder meeting on Thursday, May 28, 2026.
- What is the record date for the Strata Critical Medical Inc 2026 meeting?
- The record date for the Strata Critical Medical Inc 2026 meeting is Tuesday, March 31, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Strata Critical Medical Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Strata Critical Medical Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Strata Critical Medical Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Strata Critical Medical Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.